Regulated information

SALES FOR 1ST QUARTER 2025

First-quarter sales of Essential products totaled 85 million euros, up+ 1.8% at constant exchange rates.

Availability of the 2024 universal registration document

On 24 April 2025, Vetoquinol filed its 2024 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

2024 Annual results

Annual sales: €539m (+2.2% at constant exchange rates)
Essential products sales: €328m (+4.6% at constant exchange rates)
Net result, Group share: €59m (10.9% of sales)
EBITDA: €104m (19.3% of sales)
Cash flow generation: €86m

Annual sales 2024: €539 million

Annual sales: €539 million (up 2.2% at constant exchange rates and up 1.9%. on a reported basis)
Annual sales of Essential products: €328 million (up 4.6% at constant exchange rates and on a reported basis)

Sales at end September 2024

At the end of September 2024, Vetoquinol sales totaled €398 million, up +1.6% on a reported basis and +1.8% at constant exchange rates.

2024 half-year Results

Sales: €264m (+3.2% as reported)
Essentials products sales: €160m (+6.0% of Group sales)
Net income - Group share: €24m (9.0% of sales)
EBITDA*: €45m (17% of sales)
Cash-flow generation: €27m

2024 Half-Year Results slideshow

Contents
1. First semester 2024 results
2. Conclusion and outlook

Rapport financier semestriel 2024 (French)

Rapport financier semestriel 2024 (French)

SALES 1st quarter 2024: €134M

The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products.

Availability of the 2023 universal registration document

On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).